464 related articles for article (PubMed ID: 24769570)
1. The role of anthracyclines in the treatment of early breast cancer.
Greene J; Hennessy B
J Oncol Pharm Pract; 2015 Jun; 21(3):201-12. PubMed ID: 24769570
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant therapy for HER2 positive breast cancer: are anthracyclines still necessary?
Castrellon AB; Glück S
Clin Adv Hematol Oncol; 2008 Sep; 6(9):666-72. PubMed ID: 18827789
[TBL] [Abstract][Full Text] [Related]
3. Do anthracyclines still have a role in adjuvant chemotherapy of breast cancer?
Davidson A; Gelmon K
Future Oncol; 2011 Jan; 7(1):37-55. PubMed ID: 21174537
[TBL] [Abstract][Full Text] [Related]
4. HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials.
Gennari A; Sormani MP; Pronzato P; Puntoni M; Colozza M; Pfeffer U; Bruzzi P
J Natl Cancer Inst; 2008 Jan; 100(1):14-20. PubMed ID: 18159072
[TBL] [Abstract][Full Text] [Related]
5. Major changes in chemotherapy regimens administered to breast cancer patients during 2000-2008 in the Netherlands.
van Herk-Sukel MP; van de Poll-Franse LV; Creemers GJ; Lemmens VE; van der Linden PD; Herings RM; Coebergh JW; Voogd AC
Breast J; 2013; 19(4):394-401. PubMed ID: 23663128
[TBL] [Abstract][Full Text] [Related]
6. Emergence of nonanthracycline regimens in the adjuvant treatment of breast cancer.
Pal SK; Childs BH; Pegram M
Breast Cancer Res Treat; 2010 Jan; 119(1):25-32. PubMed ID: 19795206
[TBL] [Abstract][Full Text] [Related]
7. Taxane-based combinations as adjuvant chemotherapy for node-positive ER-positive breast cancer based on 2004-2009 data from the Breast Cancer Registry of the Japanese Breast Cancer Society.
Hojo T; Masuda N; Iwamoto T; Niikura N; Anan K; Aogi K; Ohnishi T; Yamauchi C; Yoshida M; Kinoshita T; Masuoka H; Sagara Y; Sakatani T; Kojima Y; Tsuda H; Kumamaru H; Miyata H; Nakamura S
Breast Cancer; 2020 Jan; 27(1):85-91. PubMed ID: 31327134
[TBL] [Abstract][Full Text] [Related]
8. Can we abandon anthracyclines for early breast cancer patients?
Henderson IC
Oncology (Williston Park); 2011 Feb; 25(2):115-24, 127. PubMed ID: 21456382
[TBL] [Abstract][Full Text] [Related]
9. Optimal use of anthracycline-free perioperative chemotherapy in HER2-positive breast cancer patients.
Watanuki R; Hayashida T; Kawai Y; Kikuchi M; Nakashoji A; Yokoe T; Toyota T; Seki T; Takahashi M; Kitagawa Y
Int J Clin Oncol; 2019 Jul; 24(7):807-814. PubMed ID: 30810890
[TBL] [Abstract][Full Text] [Related]
10. Role of anthracyclines in the treatment of early breast cancer.
Gianni L; Norton L; Wolmark N; Suter TM; Bonadonna G; Hortobagyi GN
J Clin Oncol; 2009 Oct; 27(28):4798-808. PubMed ID: 19687331
[TBL] [Abstract][Full Text] [Related]
11. First efficacy results of capecitabine with anthracycline- and taxane-based adjuvant therapy in high-risk early breast cancer: a meta-analysis.
Jiang Y; Yin W; Zhou L; Yan T; Zhou Q; Du Y; Shen Z; Shao Z; Lu J
PLoS One; 2012; 7(3):e32474. PubMed ID: 22396769
[TBL] [Abstract][Full Text] [Related]
12. Anthracycline Use for Early Stage Breast Cancer in the Modern Era: a Review.
Jasra S; Anampa J
Curr Treat Options Oncol; 2018 May; 19(6):30. PubMed ID: 29752560
[TBL] [Abstract][Full Text] [Related]
13. Continued value of adjuvant anthracyclines as treatment for early breast cancer.
Turner N; Biganzoli L; Di Leo A
Lancet Oncol; 2015 Jul; 16(7):e362-9. PubMed ID: 26149888
[TBL] [Abstract][Full Text] [Related]
14. Phase II Study of Neoadjuvant Anthracycline-Based Regimens Combined With Nanoparticle Albumin-Bound Paclitaxel and Trastuzumab for Human Epidermal Growth Factor Receptor 2-Positive Operable Breast Cancer.
Tanaka S; Iwamoto M; Kimura K; Matsunami N; Morishima H; Yoshidome K; Nomura T; Morimoto T; Yamamoto D; Tsubota Y; Kobayashi T; Uchiyama K
Clin Breast Cancer; 2015 Jun; 15(3):191-6. PubMed ID: 25579459
[TBL] [Abstract][Full Text] [Related]
15. Optimal adjuvant treatment for patients with HER2-positive breast cancer in 2015.
Zardavas D; Fouad TM; Piccart M
Breast; 2015 Nov; 24 Suppl 2():S143-8. PubMed ID: 26255196
[TBL] [Abstract][Full Text] [Related]
16. Response-Guided Omission of Anthracycline in Patients with HER2-Positive Early Breast Cancer Treated with Neoadjuvant Taxane and Trastuzumab: 5-Year Follow-Up of Prognostic Study Using Propensity Score Matching.
Fujita N; Fujita K; Kim SJ; Iguchi C; Nomura T; Aono T; Yanagisawa T; Enomoto Y; Inakami K; Miyagawa Y; Tomoike R; Kasugai T; Shiba E
Oncology; 2022; 100(5):257-266. PubMed ID: 35114682
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant Anthracyclines in Breast Cancer: What Is Their Role?
Shah AN; Gradishar WJ
Oncologist; 2018 Oct; 23(10):1153-1161. PubMed ID: 30120159
[TBL] [Abstract][Full Text] [Related]
18. Cardiac safety of non-anthracycline trastuzumab-based therapy for HER2-positive breast cancer.
Yu AF; Mukku RB; Verma S; Liu JE; Oeffinger KC; Steingart RM; Hudis CA; Dang CT
Breast Cancer Res Treat; 2017 Nov; 166(1):241-247. PubMed ID: 28710537
[TBL] [Abstract][Full Text] [Related]
19. Nine-Year Median Follow-up of Cardiotoxicity and Efficacy of Trastuzumab Concurrently With Anthracycline-Based and Anthracycline-Free Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer Patients.
He X; Dai X; Ji J; Liu H; Shi G; Yeung SJ
Clin Breast Cancer; 2022 Jan; 22(1):e80-e90. PubMed ID: 34312098
[TBL] [Abstract][Full Text] [Related]
20. Sequential versus concurrent anthracyclines and taxanes as adjuvant chemotherapy of early breast cancer: a meta-analysis of phase III randomized control trials.
Shao N; Wang S; Yao C; Xu X; Zhang Y; Zhang Y; Lin Y
Breast; 2012 Jun; 21(3):389-93. PubMed ID: 22542064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
